Quant Market Neutral Hedge Fund Seeks to Model Fundamental Cause-and-Effects in the Market (Opalesque)
The equity market neutral strategy, which seeks to profit from increasing and decreasing prices and keeps the total value of long and short holdings roughly equal to lower the overall risk, is an interesting one for quantitative finance, as it is the basis for many modeling possibilities. Especially if you use machine learning models and neural networks that incorporate and model the fundamental cause-and-effects in the market. This is what this London-based hedge fund does. The Kvasir Master Fund is a quant equity market neutral hedge fund that invests through the combination of market knowledge and machine learning modelling in a universe of global equities and futures that offer scope for diversification.
Third Point Sharply Boosts Exposure to Equities (Institutional Investor)
But the multistrat fund headed by Dan Loeb is also very bullish on credit. Third Point has significantly increased its equity exposure in recent weeks.In its second-quarter letter, made public Thursday, the multistrategy hedge fund headed by Dan Loeb told clients that after taking exposures “to almost zero,” in recent weeks, it has lifted its net exposure to over 40 percent as it identified…
Funds Amass Record Wager on Hawkish Fed as Jackson Hole Looms (Reuters)
As global markets’ focus rests squarely on Fed chief Jerome Powell’s keynote address at Jackson Hole on Friday, hedge funds have built up their largest-ever bet on higher U.S. interest rates. Not only are they holding a record short position in “SOFR” rates futures of almost 1 million contracts, according to Commodity Futures Trading Commission data, but the pace at which they have accumulated that wager has been startling.
Monday 8/22 Insider Buying Report: SRPT, DISH (Nasdaq.com)
At Sarepta Therapeutics (SRPT), a filing with the SEC revealed that on Friday, Director Michael Andrew Chambers purchased 46,170 shares of SRPT, at a cost of $108.28 each, for a total investment of $5M. Sarepta Therapeutics is trading up about 2.2% on the day Monday. And at DISH Network Corp (DISH), there was insider buying on Wednesday, by James Defranco who purchased 160,373 shares for a cost of $18.53 each, for a trade totaling $2.97M. Before this latest buy, Defranco bought DISH at 3 other times during the past year, for a total cost of $25.03M at an average of $19.40 per share. DISH Network Corp is trading off about 2% on the day Monday. Investors are able to bag DISH at a price even lower than Defranco did, with shares changing hands as low as $17.94 at last check today — that’s 3.2% below Defranco’s purchase price.
$92 Million Bet On This Penny Stock? Also Check Out Other 3 Stocks Under $5 Insiders Are Buying (Benzinga)
Summit Therapeutics: The Trade: Summit Therapeutics Inc. (SMMT) CEO Robert W Duggan acquired a total of 94,849,203 shares at an average price of $0.97. To acquire these shares, it cost around $92 million.
